Breaking News

Tesco to Investigate Overstatement of Profit by About $410M
Tweet TWEET

Women With Dense Breasts Are at Higher Risk for Cancer

Women With Dense Breasts Are at Higher Risk for Cancer 
Atossa Genetics' New 'Pap Smear for the Breast' Test Can Spot Signs
of Precancerous Changes Long Before Cancer Occurs, Helping to Protect
These Women From Cancer 
SEATTLE, WA -- (Marketwire) -- 02/04/13 --  Atossa Genetics, Inc.
(NASDAQ: ATOS) announced that its new ForeCYTE Breast Health System
addresses the problem of detecting not only cancer, but also the
early cellular changes that lead to cancer, in women with dense
breasts.  
Numerous studies have shown that women with denser breast tissue, and
thus more gland tissue and less fatty tissue, are at higher risk for
breast cancer. Moreover, as the American Cancer Society (ACS)
explains, "Dense breast tissue can also make it harder for doctors to
spot problems on mammograms." (ACS Guidelines.) 
This is why five states -- California, Texas, New York, Connecticut
and Virginia -- have passed legislation requiring that women whose
mammograms show dense breasts must be notified of this fact, and
several other states and the U.S. Congress are considering such
legislation. For instance, the New York law, which took effect
January 19, 2013, states that mammography patients with dense breasts
must be told: "Your mammogram shows that your breast tissue is dense.
Dense breast tissue is very common and is not abnormal. However,
dense breast tissue can make it harder to find cancer on a mammogram
and may also be associated with an increased risk of breast cancer." 
One key study highlights those risks. Scientists at the University of
California, San Francisco examined aspirated fluid from the breasts
of 2,700 women between the ages of 25 to 65. This fluid contains duct
cells, which are responsible for more than 90 percent of breast
cancers. The study found that women with dense breasts were more than
four times more likely than women without dense breasts to have a
condition called atypical hyperplasia -- in which the cells seem to
grow too quickly and pile up on each other. These atypical cells
represent the first steps on the path to cancer. As a result,
spotting these cells is not only key to detecting the risk of cancer
in these women; it also opens the door to treating the condition and
halting the progression to cancer.  
"It is vital that we understand the limits of mammography and give
women a better test -- one that is capable of detecting the earliest
signs of precancer," said Steven C. Quay, M.D., Ph.D., FCAP, Atossa
Genetics' Chairman of the Board and Chief Executive Officer.  
In January, Atossa Genetics launched such a diagnostic: the ForeCYTE
Breast Health Test. The test, cleared by the U.S. Food & Drug
Administration, uses a breast pump called the Mammary Aspirate
Specimen Cytology Test (MASCT) to painlessly collect miniscule
amounts of fluid from the milk ducts in women's breasts, analyzes the
duct cells for hyperplasia and other abnormalities, and analyzes for
genetic mutations. 
In essence, this test is like a Pap smear for cancer, spotting the
earliest cellular warnings up to eight years before cancer can be
detected by any other method. Women with dense breasts, therefore,
could be monitored every year or so for signs of atypical
hyperplasia. As long as the results come back negative, these women
could lead normal lives without fear of cancer. But if hyperplasia is
detected, women could be treated to reverse the condition.  
"Just as Pap smears have reduced cervical cancer rates by over 75
percent, becoming the most successful screening test in medicine,
this test can detect the precursor changes that lead to breast cancer
-- and make prevention possible," says Quay. "We believe this test
should be mandatory for women with dense breasts."  
To use Atossa's ForeCYTE Breast Health System, see your doctor. The
Atossa test is being distributed to health care providers nationwide
by Clarity Women's Health (a division of Diagnostic Test Group, LLC)
of Boca Raton, Florida. (See press release.) 
For background and additional information on breast density
legislation, see WSJ online. 
About Atossa Genetics, Inc.
 Atossa Genetics, Inc. (NASDAQ: ATOS),
The Breast Health Company(TM), is based in Seattle, Washington, and
is focused on preventing breast cancer through the commercialization
of patented, FDA-cleared diagnostic medical devices and patented,
laboratory developed tests (LDT) that can detect precursors to breast
cancer up to eight years before mammography, and through research and
development that will permit it to commercialize treatments for
pre-cancerous lesions. 
The National Reference Laboratory for Breast Health (NRLBH), a wholly
owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified
high-complexity molecular diagnostic laboratory located in Seattle,
WA, that provides the patented ForeCYTE Breast Health Test, a risk
assessment test for women 18 to 73 years of age akin to the Pap
smear, and the ArgusCYTE Breast Health Test, a blood test for
recurrence in breast cancer survivors that provides a "liquid biopsy"
for circulating cancer cells and a tailored treatment plan for
patients and their caregivers. 
Forward-Looking Statements
 Except for the historical information
contained herein, the matters set forth in this press release,
including statements regarding Atossa's plans, expectations,
projections, potential opportunities, goals and objectives are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from
the anticipated or estimated future results, including the risks and
uncertainties associated with the efficacy of Atossa's products and
services, the market demand for and acceptance of Atossa's products
and services and other risks set forth in Atossa's filings with the
U.S. Securities and Exchange Commission, including the Registration
Statement on Form S-1 filed with the SEC on January 28, 2013. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Atossa undertakes no obligation to revise
or update any forward-looking statement to reflect events or
circumstances after the issuance of this press release. 
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2219020 
Contact: 
Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP 
Chairman, President and CEO of Atossa Genetics and 
Director of the National Reference Laboratory for Breast Health
800-351-3902
Steven.Quay@AtossaGenetics.com 
Adam Holdsworth (Investor Relations)
Dian Griesel Inc. (DGI)
212-825-3210
adam@dgicomm.com 
 
 
Press spacebar to pause and continue. Press esc to stop.